Population-based survival data for brain tumors in Korea
- 292 Downloads
Primary brain tumors are relatively uncommon but particularly lethal cancers. Although survival is useful for monitoring the effects of early cancer detection and treatment, there are few population-based estimates of survival for subjects with brain tumors, especially in Asian countries. Using the Korea National Cancer Incidence Database, 4,721 newly diagnosed cases of histologically confirmed malignant primary brain tumors from 1999 to 2004 were analyzed for observed survival. For trend analyses of glioblastomas, we included 2,751 glioblastoma cases diagnosed between 1999 and 2007. We compared survival by age group and histological type by use of the Kaplan–Meier method. For all ages and all brain tumor types in Korea, five-year survival was 37.5 %. For each histological type of brain tumor survival of pediatric and younger adult populations was much better than that of older adults. Five-year survival for glioblastoma, astrocytoma, anaplastic astrocytoma, and oligodendroglioma was 8.9, 51.6, 25.2, and 73.5 %, respectively. Two-year survival for glioblastoma increased from 18.6 % for cases diagnosed in 1999–2001 to 21.3 % for cases diagnosed in 2002–2004 and to 24.7 % for cases diagnosed in 2005–2007. These results may help clinicians and patients to assess long-term prognoses for brain tumors, and the data presented here could serve as master control data set for single-arm clinical trials, especially in Asian populations.
KeywordsBrain tumor Cancer registry Epidemiology Survival
This work was supported by a research grant from the National Cancer Center (no. 1010160).
Conflict of interest
The authors have no personal financial or institutional interest in any of the drugs, materials, or devices described in this article.
- 1.Bauchet L, Rigau V, Mathieu-Daudé H, Figarella-Branger D, Hugues D, Palusseau L, Bauchet F, Fabbro M, Campello C, Capelle L, Durand A, Trétarre B, Frappaz D, Henin D, Menei P, Honnorat J, Segnarbieux F (2007) French brain tumor data bank: methodology and first results on 10,000 cases. J Neurooncol 84:189–199PubMedCrossRefGoogle Scholar
- 2.CBTRUS (2011) Statistical report: primary brain tumors diagnosed in the United States, 2004–2007. The Central Brain Tumor Registry of the United States, HindsdaleGoogle Scholar
- 5.Deorah S, Lynch CF, Sibenaller ZA, Ryken TC (2006) Trends in brain cancer incidence and survival in the United States: Surveillance, Epidemiology, and End Results program, 1973 to 2001. Neurosurg Focus 20(4): E1Google Scholar
- 10.Reis L, Eisner M, Kosary C, Hankey B, Miller B, Clegg L, Edwards B (2000) SEER Cancer Statistics Review, 1973–1997. National Cancer Institute, Bethesda, MDGoogle Scholar
- 14.Davis FG, Freels S, Grutsch J, Barlas S, Brem S (1998) Survival rates in patients with primary malignant brain tumors stratified by patient age and tumor histological type: an analysis based on surveillance, epidemiology, and end results (SEER) data, 1973–1991. J Neurosurg 88:1–10PubMedCrossRefGoogle Scholar
- 18.Weller M, Gorlia T, Cairncross JG, van den Bent MJ, Mason W, Belanger K, Brandes AA, Bogdahn U, Macdonald DR, Forsyth P, Rossetti AO, Lacombe D, Mirimanoff RO, Vecht CJ, Stupp R (2011) Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma. Neurology 77:1156–1164PubMedCrossRefGoogle Scholar
- 19.Scoccianti S, Magrini SM, Ricardi U et al (2010) Patterns of care and survival in a retrospective analysis of 1059 patients with glioblastoma multiforme treated between 2002 and 2007: a multicenter study by the Central Nervous System Study Group of Airo (Italian Association of Radiation Oncology). Neurosurgery 67:446–458PubMedCrossRefGoogle Scholar
- 21.Stark-Vance V (2005) Bevacizumab and CPT-11 in the treatment of relapsed malignant glioma (Abstract). Neurooncology 7:369Google Scholar
- 24.Cardinale R, Won M, Choucair A, Gillin M, Chakravarti A, Schultz C, Souhami L, Chen A, Pham H, Mehta M (2006) A phase II trial of accelerated radiotherapy using weekly stereotactic conformal boost for supratentorial glioblastoma multiforme: RTOG 0023. Int J Radiat Oncol Biol Phys 65:1422–1428PubMedCrossRefGoogle Scholar
- 25.Larson DA, Suplica JM, Chang SM, Lamborn KR, McDermott MW, Sneed PK, Prados MD, Wara WM, Nicholas MK, Berger MS (2004) Permanent iodine 125 brachytherapy in patients with progressive or recurrent glioblastoma multiforme. Neurooncol 6:119–126Google Scholar
- 28.Simon JM, Cornu P, Boisserie G, Hasboun D, Tep B, Hardiman C, Valery CA, Delattre JY, Dormont D, Baillet F, Mazeron JJ (2002) Brachytherapy of glioblastoma recurring in previously irradiated territory: predictive value of tumor volume. Int J Radiat Oncol Biol Phys 53:67–74PubMedCrossRefGoogle Scholar
- 29.Won YJ, Sung J, Jung KW, Kong HJ, Park S, Shin HR, Park EC, Ahn YO, Hwang IK, Lee DH, Choi JS, Kim WC, Lee TY, Yoo CI, Bae JM, Kim ON, Chung W, Kong IS, Lee DH, Lee JS (2009) Cancer statistics in Korea: incidence, mortality and survival in 2005. Cancer Res Treat 41:122–131PubMedCrossRefGoogle Scholar